ARGX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AR

Mkt Cap

$51.50B

Volume

334.23K

Next Earnings

October 22nd

Loading chart

AR

ARGXargenx SE American Depositary Shares

ARGX

Pay with—

Available Balance0.00

AR

Mkt Cap

$53.22B

Volume

334.23K

Next Earnings

October 22nd

Chart Earnings News About Insider Filings

Zacks Investment Ideas feature highlights: Cummins, Argenx and PACCARAs AI stocks experience a selloff, Zacks highlights three non-AI stocks with strong fundamentals and growth potential: Cummins (engine/powertrain manufacturer benefiting from data center boom), Argenx (biotech with blockbuster autoimmune drug Vyvgart expanding to new indications), and PACCAR (commercial truck manufacturer with 87 years of profitability). All three are trading at discounts from recent highs with positive earnings outlooks.Zacks Investment Research · Oct 16, 2026

Best 3 Non-AI Stocks to Buy Now on the Dip Amid the AI Stock SelloffWhile AI stocks experienced a selloff, three non-AI companies present attractive long-term investment opportunities: Cummins (CMI), a historic engine manufacturer benefiting from data center demand and trading 29% below summer highs; Argenx (ARGX), a biotech firm with its blockbuster autoimmune drug Vyvgart expanding to new indications; and PACCAR (PCAR), a truck manufacturer positioned to benefit from fleet refreshes and constrained freight capacity.Zacks Investment Research · Oct 15, 2026

Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth TodayA $1,000 investment in Halozyme Therapeutics (HALO) made in October 2016 would be worth $11,612.33 as of October 15, 2026, representing a 1,061.23% gain. This significantly outperformed the S&P 500's 261.89% return over the same period. The biopharmaceutical company's success is driven by royalties from its ENHANZE drug delivery technology licensed to major pharma partners, though it faces headwinds from biosimilar competition on blockbuster drugs.Zacks Investment Research · Oct 15, 2026

argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026argenx announced it will host a conference call on October 22, 2026 at 2:30 PM CET to discuss third quarter 2026 financial results and provide a business update. The immunology company will present via webcast and phone with dial-in numbers provided for multiple countries.GlobeNewswire Inc. · Oct 15, 2026

argenx Meets Primary Endpoint in Phase II Celiac Disease Studyargenx announced positive phase II results for FB102, an investigational therapy for celiac disease, meeting its primary endpoint with significant improvements in intestinal tissue measures versus placebo and no new safety signals. The company plans to advance FB102 into late-stage development and evaluate it for other autoimmune conditions. However, the stock declined nearly 12% following a separate announcement that argenx discontinued its phase III UNITY study for Vyvgart Hytrulo in Sjögren's disease.Zacks Investment Research · Oct 9, 2026

HALO Wins Court Order Blocking Merck's Keytruda SC in EuropeA Dutch patent court ruled that Merck's Keytruda subcutaneous formulation infringes Halozyme's MDASE patent, ordering Merck to cease manufacturing and sales across eight European markets. The ruling does not affect Keytruda's intravenous version. This marks another legal victory for Halozyme against Merck, though the company clarified that its separate ENHANZE technology and licensing business remain unaffected.Zacks Investment Research · Oct 8, 2026

HALO Expands ENHANZE Collaboration & Licensing Deal With ARGXHalozyme Therapeutics announced an expansion of its collaboration with argenx, increasing exclusive ENHANZE technology targets from six to eight. The deal includes milestone payments and royalties on product sales. Halozyme raised its 2026 revenue guidance to $1.84-$1.91 billion, driven by strong royalty growth from J&J's Darzalex and argenx's Vyvgart Hytrulo.Zacks Investment Research · Oct 7, 2026

10 Wall Street Analysts Think Argenx Stock Is Headed to At Least $1,200 -- Is the Stock a Buy Now?Wall Street analysts are overwhelmingly bullish on Argenx SE (ARGX), with 10 analysts predicting the stock will reach at least $1,200 within 12 months from its current price of $919, representing potential upside of roughly 29%. The optimism is driven by strong sales growth from its Vyvgart franchise and a promising pipeline of autoimmune disease treatments. However, the company faces risks from ongoing clinical trials and declining sales in China.The Motley Fool · Oct 5, 2026

argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipelineargenx presented new clinical data at the AANEM and MGFA scientific sessions demonstrating deepening improvements in ocular myasthenia gravis (MG) with VYVGART, sustained one-year efficacy in anti-AChR antibody-negative MG patients, and benefits of earlier treatment initiation. Real-world evidence from over 1,100 U.S. MG patients showed greater clinical gains when treatment started within one year of diagnosis. Long-term CIDP data reinforced consistent safety and efficacy, with a Phase 4 study supporting direct transition from IVIg. Pipeline candidates empasiprubart and adimanebart showed promising Phase 2 results in multifocal motor neuropathy and congenital myasthenic syndrome respectively.GlobeNewswire Inc. · Sep 29, 2026

argenx Completes Acquisition of Forte Biosciences, Inc.argenx successfully completed its acquisition of Forte Biosciences for $77.00 per share in cash, adding FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease. The acquisition expands argenx's immunology portfolio and supports its Vision 2030 strategy to become a leading immunology innovation company by targeting diseases with limited treatment options.GlobeNewswire Inc. · Aug 27, 2026

to start trading

AR

ARGXargenx SE American Depositary Shares

ARGX

Pay with—

Available Balance0.00

Your PositionYou don't own any ARGX yet.

Related Tickers

Earnings